SCHEMBL9564052

SCHEMBL9564052

Cc1cccc(N2CCC2=O)c1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.62
ALOX5 P09917 3/20 0.54
HSD11B1 P28845 3/20 0.50
HSP90AA1 P07900 1/20 0.50
MGLL Q99685 1/20 0.50
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
MAPT P10636 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NPC1 O15118 2/20 0.48
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
ADRB1 P08588 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1459903 0.89 ALDH1A1 (0.62) L3MBTL1ALOX5ALDH1A1CYP1A2CYP3A4
SCHEMBL12795836 0.88 L3MBTL1 (0.57) L3MBTL1ALOX5HSD11B1HSP90AA1MGLL
SCHEMBL1750871 0.86 L3MBTL1 (0.56) L3MBTL1ALOX5HSD11B1HSP90AA1MGLL
SCHEMBL25575682 0.85 L3MBTL1 (0.54) L3MBTL1ALOX5HSD11B1HSP90AA1MGLL
SCHEMBL6401435 0.84 L3MBTL1 (0.53) L3MBTL1ALOX5HSD11B1HSP90AA1MGLL
SCHEMBL23601592 0.82 L3MBTL1 (0.46) L3MBTL1ALOX5
SCHEMBL5605334 0.80 POLB (0.46) L3MBTL1HSP90AA1HSD17B10
SCHEMBL30516650 0.80 ALOX5 (0.55) ALOX5MGLLALDH1A1CYP1A2CYP3A4
SCHEMBL25366082 0.80 ALOX5 (0.55) ALOX5MGLLALDH1A1CYP1A2CYP3A4
SCHEMBL12879707 0.80 L3MBTL1 (0.51) L3MBTL1ALOX5HSD11B1HSP90AA1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-12-21 US disclosed
US-9815818-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2017-11-14 US disclosed
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed
EP-0534359-A1 Process for preparing arylene sulfide polymers PHILLIPS PETROLEUM COMPANY (US) 1993-03-31 EP disclosed
US-5110902-A High molecular weight polythioether-sulfones PHILLIPS PETROLEUM COMPANY (US) 1992-05-05 US disclosed
US-5086163-A High molecular weight polymers formed by contacting dihaloaromatic sulfone with complex of alkali metal aminoalkanoate and alkalimetal hydrosulfide PHILLIPS PETROLEUM COMPANY (US) 1992-02-04 US disclosed
US-5023315-A Reacting dihaloaromatic component with complex of lactams, alkali hydroxide and sulfur source, such as alkali metal bisulfide, thiolactam or hydrogen sulfide; whiteness, purity PHILLIPS PETEROLEUM COMPANY (US) 1991-06-11 US disclosed
US-5015725-A Heat resistant thermoplastic resins for electrical components, aircraft or automobile parts, protective coatings PHILLIPS PETROLEUM COMPANY (US) 1991-05-14 US disclosed
EP-0309955-A1 Aromatic sulfide/sulfone polymer production PHILLIPS PETROLEUM COMPANY (US) 1989-04-05 EP disclosed
EP-0039508-B1 A PROCESS FOR PREPARING ALKALI METAL AMINO ALKANOATES AND USE OF SAME PHILLIPS PETROLEUM COMPANY (US) 1984-03-07 EP disclosed
US-4371706-A SALT FORMATION, HYDROLYSIS PHILLIPS PETROLEUM COMPANY (US) 1983-02-01 US disclosed
US-4324886-A POLYMERIZATION OF POLYHALO AROMATIC COMPOUND AND HYDROGEN SULFIDE PHILLIPS PETROLEUM COMPANY (US) 1982-04-13 US disclosed
EP-0039508-A1 A process for preparing alkali metal amino alkanoates and use of same PHILLIPS PETROLEUM COMPANY (US) 1981-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362201-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS L3MBTL1 3141/4885ALOX5 668/4885HSD11B1 4061/4885
US-20170008873-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS L3MBTL1 3141/4885ALOX5 668/4885HSD11B1 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.